Who is not suitable for deuterated colexitinib (decavatinib)?

Deucravacitinib is an oral, selective TYK2 inhibitor primarily used to treat patients with moderate to severe plaque psoriasis. However, not all patients are suitable for this drug, and some require careful evaluation before use or are prohibited from using it entirely. First of all, pregnant and lactating women should avoid using decavatinib because the drug may affect fetal or infant development through the placenta or breast milk, and there is a lack of sufficient safety data at this stage.

Secondly, patients with severe liver or renal impairment should use it with caution or under strict supervision by a physician. Decavatinib is excreted after liver metabolism. If liver function is damaged, accumulation of the drug in the body may increase the risk of adverse reactions, such as increased blood lipids and increased risk of infection. Similarly, the reduced drug metabolism and excretion capacity in patients with severely impaired renal function may also lead to an increase in blood drug concentration and increase the incidence of adverse events. Therefore, it is necessary to adjust the dosage or choose alternative treatment according to the guidance of a doctor.

In addition, patients with severe infections or compromised immune systems are not candidates for decavatinib. As a TYK2 inhibitor, it inhibits immune signaling pathways and may reduce the body's ability to resist viral, bacterial or fungal infections. Patients who are receiving immunosuppressive treatment or have chronic infectious diseases such as active tuberculosis and hepatitis must conduct a comprehensive evaluation before using this drug, and take preventive measures or delay medication if necessary to prevent the risk of infection from worsening.

Finally, patients who are allergic to drug ingredients should not use decavatinib. Drug allergy may cause serious reactions such as rash, difficulty breathing, and drop in blood pressure, and in some cases may even be life-threatening. During use, if unexplained allergic symptoms occur, you should stop taking the medicine immediately and seek medical advice. In short, although decavatinib is an effective drug for the treatment of psoriasis, it should be used with caution or contraindicated in people who are pregnant, lactating, have severe liver and kidney insufficiency, have low immune function, or are allergic to drugs. Individualized medication must be carried out under the guidance of a professional doctor.

Reference materials:https://www.drugs.com/